This success is attributed to the reciprocal communication between the liver and adipose tissue, which adjusts to changes in energy requirements59.A recently study found that GW9662, a PPARγ antagonist, attenuates NAFLD progression by reducing hepatic steatosis, inflammation, and oxidative stress103. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.